查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933899

罕见自体发炎性疾病治疗市场（按药物类别、给药途径、适应症、通路和最终用户划分），全球预测，2026-2032年

Rare Autoinflammatory Diseases Drug Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，罕见自体发炎性疾病治疗市场规模将达到 37.8 亿美元，到 2026 年将成长至 41.3 亿美元，复合年增长率为 9.70%，到 2032 年将达到 72.3 亿美元。

关键市场统计数据
基准年 2025 37.8亿美元
预计年份：2026年 41.3亿美元
预测年份 2032 72.3亿美元
复合年增长率 (%) 9.70%

全面概述罕见自身发炎性疾病，重点关注不断发展的诊断方法、治疗方法创新以及影响临床和商业性决策的系统性挑战。

罕见自体发炎性疾病是一组在遗传和免疫学上各不相同的疾病，其特征是先天免疫活化失控、阵发性全身性发炎和多重器官功能障碍。近年来，分子诊断技术的进步、治疗方法的拓展以及患者权益倡导的活性化，重塑了临床诊疗路径，并吸引了生物製药公司、支付方和专科药房的日益关注。儘管取得了这些进展，临床实务仍然十分复杂。表型异质性、诊断延迟以及对标靶治疗方法的持续未满足需求，仍是医疗服务面临的挑战。

诊断突破、细胞激素标靶治疗、监管柔软性和数位化医疗模式如何重塑罕见自身发炎性疾病的治疗路径和商业策略

过去几年，罕见自体发炎性疾病的诊断、治疗和患者取得方式发生了翻天覆地的变化。基因定序和通路特异性生物标记实现了早期精准诊断，推动精准医疗从概念走向实践。这些诊断能力的提升加速了标靶治疗适用患者的筛选，并为临床试验入组和核准后证据的产生建立了明确的衡量标准。同时，治疗创新也转向了细胞激素靶向生物製剂和新型小分子抑制剂，旨在抑制特定的发炎介质，同时减少传统皮质类固醇的脱靶效应。

评估新兴关税趋势将如何改变生物製药供应链、分销经济、临床试验物流以及整个治疗价值链的准入策略。

2025年生效的新关税可能会重塑依赖复杂供应链和进口组件的治疗药物的生产、分销和定价策略。生物製药通常需要专门的生产投入和无菌低温运输物流，因此对进口成本的变化特别敏感。如果关税调整导致到岸成本上升，製造商可能立即面临重新评估筹资策略、调整受影响市场产品价格或降低利润以维持病患用药的压力。随着时间的推移，这些压力可能会加速製造地的策略转变，包括提高生产在地化程度以及在免税地区扩大第三方灌装包装伙伴关係。

将特定适应症、亚表型、治疗层级、给药途径、分销模式和年龄组与商业化和临床策略联繫起来的高精度細項分析

了解不同细分领域的细微差别对于设计有效的罕见自体发炎性疾病临床和商业策略至关重要。我们的适应症组合包括冷吡啉相关週期性症候群、遗传性地中海热、高免疫球蛋白D症候群和肿瘤坏死因子受体相关週期性症候群。在冷吡啉相关症候群中，不同的临床表型，例如遗传性寒冷自体发炎症候群、Muckle-Wells症候群和新生儿起病的多系统发炎性疾病，会产生不同的诊断和治疗需求。这些临床亚型需要不同的研究终点、不同的安全性优先事项和不同的长期监测需求，进而影响研究设计和证据产生途径。

美洲、欧洲、中东和非洲以及亚太地区的区域性需求和微妙的市场动态影响市场准入、证据要求和生产选择。

区域趋势对罕见自体发炎性疾病市场的研发重点、进入途径和商业性执行有显着影响。在美洲，监管路径和支付体系支持重点关注新型生物製药的快速上市、强大的患者支持网络以及先进的临床试验基础设施，尤其是那些能够识别和招募具有明确遗传亚型患者的基础设施。同时，某些市场的价格敏感性和支付方的严格审查促使製造商加强对疗效证据和患者支持服务的投入，以维持药物的普及。在进口相关成本和不断变化的贸易政策会影响治疗总成本的地区，供应链的韧性和製造地的接近性是关键的考量。

策略性企业行动包括有针对性的生物製药开发、製剂创新、诊断伙伴关係以及旨在实现差异化和促进获取途径的合作。

在该治疗领域运作的公司正采取差异化的策略策略，以平衡科学风险、商业可行性和商业性潜力。鑑于IL-1或IL-6讯号路径在多种自体发炎性疾病中具有强有力的机制证据，主要企业优先研发标靶IL-1或IL-6讯号路径的特异性生物製药製剂；而其他公司则致力于研发小分子抑制剂或老药新用药物，以期获得给药途径或成本优势。在整个竞争格局中，各公司都在投资製剂研发，以实现皮下和口服给药，从而拓展处方途径并减少对输液中心的依赖。

为确保价值链的韧性，开发商和支付方应专注于以下实际策略事项：透过投资製剂和诊断技术扩大患者可及性，并展现永续价值。

产业领导者应采取一系列切实可行的措施，以确保稳健的研发路径和持续的病患用药。首先，需要投资供应链多元化和替代生产方式，以降低贸易中断风险，并维护生物製药的低温运输完整性。其次，在临床适用的情况下，优先开发皮下或口服製剂，这将有助于扩大治疗场所，使其不再局限于输液中心，并提高患者的便利性和依从性。第三，在研发早期阶段就纳入卫生经济学规划，以产生支付方日益重视的高成本疗法所需的比较疗效和长期疗效证据。

调查方法概述：结合混合式一手访谈、系统性二手证据综合和迭代检验，以确保为相关人员提供可靠且可操作的研究结果。

本分析所依据的研究结合了结构化的初步研究（与领域专家的对话）和系统的二手证据综合，以确保研究结果的可靠三角验证。初步研究包括对自身发炎综合征临床医生、供应链和分销主管、监管事务专家以及患者权益倡导者进行深入访谈，以了解实际运作情况和未满足的需求。二级资讯来源包括同行评审的临床文献、监管核准和指导文件、已发表的临床试验通讯协定以及汇总的临床註册报告，从而使分析建立在检验的临床和政策进展之上。

整合科学进步、营运需求和区域贸易影响，以确定从治疗创新到患者持续获得治疗的可行路径。

罕见自体发炎性疾病领域既蕴含着巨大的科学机会，也面临着营运上的复杂性。标靶治疗和诊断技术的进步为改善治疗效果开闢了重要途径，但要充分发挥这些潜力，需要製定综合策略，以应对生产、分销、医保参与和患者识别等方面的挑战。治疗方法类型、给药途径和分销管道之间的相互作用，将决定临床应用模式以及不同患者群体中治疗模式的长期永续性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 罕见自体发炎性疾病药物市场（依药物类别划分）

  • 生物製药
    • IL-1抑制剂
    • IL-6抑制剂
    • TNF抑制剂
  • 皮质类固醇
  • 小分子抑制剂

9. 罕见自体发炎性疾病药物市场（依给药途径划分）

  • 静脉注射
  • 口服
  • 皮下注射

第十章：罕见自体发炎性疾病药物市场（依适应症划分）

  • 冷吡啉相关週期性综合症
    • 遗传性寒冷自体发炎症候群
    • 麦考尔-韦尔斯症候群
    • 新生儿发病的多系统发炎性疾病
  • 遗传性地中海热
  • 高免疫球蛋白D症候群
  • 肿瘤坏死因子受体相关週期性综合征

第十一章 罕见自体发炎性疾病药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：按最终用户分類的罕见自体发炎性疾病药物市场

  • 成年患者
  • 老年患者
  • 儿童患者

第十三章：各地区罕见自体发炎性疾病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：罕见自身发炎性疾病药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：各国罕见自体发炎性疾病药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国罕见自体发炎性疾病治疗市场

第十七章：中国罕见自体发炎性疾病治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AB2 Bio Ltd
  • ACELYRIN, Inc.
  • Aslan Pharmaceuticals Limited
  • BioCryst Pharmaceuticals, Inc.
  • CSL Behring GmbH
  • Humanigen, Inc.
  • Immedica Pharma AB
  • Inmagene Biopharmaceuticals
  • Janssen Biotech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Mabpharm Limited
  • Novartis AG
  • Pharming Group NV
  • Regeneron Pharmaceuticals, Inc.
  • RPharm
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited
Product Code: MRR-C36616F699B2

The Rare Autoinflammatory Diseases Drug Market was valued at USD 3.78 billion in 2025 and is projected to grow to USD 4.13 billion in 2026, with a CAGR of 9.70%, reaching USD 7.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.78 billion
Estimated Year [2026] USD 4.13 billion
Forecast Year [2032] USD 7.23 billion
CAGR (%) 9.70%

A comprehensive orientation to rare autoinflammatory disorders highlighting diagnostic evolution, therapeutic innovation, and systemic challenges influencing clinical and commercial decisions

Rare autoinflammatory diseases represent a group of genetically and immunologically distinct conditions characterized by dysregulated innate immune activation, episodic systemic inflammation, and multi-organ involvement. Over recent years, advancements in molecular diagnostics, an expanding therapeutic armamentarium, and a growing patient advocacy movement have reshaped clinical pathways and heightened interest across biopharma, payers, and specialty pharmacies. Despite these advances, the clinical landscape remains complex: heterogeneous phenotypes, delayed diagnosis, and an unmet need for durable, targeted therapies continue to challenge care delivery.

Clinicians increasingly rely on genetic testing and biomarker-guided approaches to differentiate entities such as cryopyrin-associated periodic syndromes, familial Mediterranean fever, and other monogenic autoinflammatory disorders from autoimmune and infectious causes. At the same time, therapeutic modalities have evolved from broad immunosuppression toward precision biologics that target specific cytokine pathways. This transition has introduced new considerations around route of administration, long-term safety, and real-world adherence, especially across adult, geriatric, and pediatric populations.

Consequently, stakeholders must navigate a multi-dimensional ecosystem that includes evolving regulatory expectations, novel distribution channels, and shifting payer dynamics. The combination of scientific progress and operational complexity now demands integrated strategies that bridge clinical development, health economics, and patient-centric access solutions. In the sections that follow, we examine the transformative inflection points, regulatory and trade headwinds, and segmentation- and region-specific insights that should guide planning for the next phase of innovation and commercialization.

How diagnostic breakthroughs, cytokine-targeted therapies, regulatory agility, and digital care models are reshaping treatment pathways and commercial strategy in rare autoinflammatory disease

The last several years have ushered in transformative shifts that have redefined how rare autoinflammatory diseases are diagnosed, treated, and delivered to patients. Precision medicine has moved from concept to practice as genetic sequencing and pathway-focused biomarkers enable earlier and more accurate diagnoses. These diagnostic capabilities have accelerated patient identification for targeted therapies, creating clearer signals for clinical trial enrollment and post-approval evidence generation. Simultaneously, therapeutic innovation has pivoted toward cytokine-targeted biologics and novel small molecule inhibitors that aim to suppress specific inflammatory mediators with fewer off-target effects than traditional corticosteroids.

Concurrently, regulatory frameworks have adapted to the realities of rare disease development, with expedited review pathways and increased willingness to accept surrogate endpoints under certain conditions. This regulatory agility has encouraged developers to explore adaptive trial designs and hybrid real-world/clinical evidence strategies to demonstrate meaningful benefit in small, heterogenous populations. Digital health and telemedicine have further transformed care pathways, increasing access to specialist clinicians and enabling remote monitoring of disease activity, which enhances both clinical management and post-marketing surveillance.

Finally, commercial models are evolving as distribution channels diversify and payers emphasize value-based arrangements. Manufacturers are responding by investing in patient support programs, alternative dosing formulations, and real-world evidence platforms to demonstrate long-term benefit and cost-effectiveness. Taken together, these shifts create a landscape in which scientific innovation and pragmatic commercialization strategies must be tightly integrated to convert clinical promise into sustained patient access.

Assessing how new tariff dynamics can alter biologics supply chains, distribution economics, clinical trial logistics, and access strategies across the therapeutic value chain

The introduction of new tariff measures in 2025 has the potential to reshape manufacturing, distribution, and pricing strategies for therapies that rely on complex supply chains and imported components. Biologics, which often require specialized manufacturing inputs and sterile cold-chain logistics, are particularly sensitive to changes in import costs. When tariff adjustments increase landed costs, manufacturers may face immediate pressure to reassess sourcing strategies, reprice products in affected markets, or absorb margins to preserve patient access. Over time, such pressures can accelerate strategic shifts in manufacturing footprint, including increased regionalization of production or expanded third-party fill/finish partnerships in tariff-exempt jurisdictions.

Distribution channels will also absorb the cumulative impact of tariffs. Hospital pharmacies that procure high-cost biologics for inpatient or infusion-based care may face procurement constraints, prompting greater reliance on outpatient administration or subcutaneous alternatives that reduce hospital resource utilization. Online and retail pharmacies, which can facilitate home-delivery models and patient support services, may see growth as stakeholders seek to mitigate distribution friction. Payers and health systems will intensify scrutiny of channel economics and may negotiate different contracting terms or demand outcomes-based arrangements to offset the financial uncertainty introduced by tariff changes.

Clinical development and global trial planning are not immune. Sponsors may reconsider trial site selection to reduce exposure to tariff-affected logistics for investigational product shipments and ancillary supplies. Regulatory interactions could become more complex as authorities weigh the downstream effects of tariffs on drug availability and continuity of care. In sum, the tariff environment underscores the importance of supply chain resilience, multi-jurisdictional manufacturing strategies, and flexible commercial models that can preserve both innovation and patient access under shifting trade conditions.

Deeply granular segmentation insights linking specific indications, sub-phenotypes, therapeutic classes, routes, distribution patterns, and age cohorts to commercialization and clinical strategies

Segment-level nuance is central to designing effective clinical and commercial strategies for rare autoinflammatory diseases. The portfolio of indications includes cryopyrin-associated periodic syndromes, familial Mediterranean fever, hyperimmunoglobulin D syndrome, and tumor necrosis factor receptor associated periodic syndrome; within cryopyrin-associated syndromes, distinct clinical phenotypes such as familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease create divergent diagnostic and therapeutic needs. These clinical subtypes drive heterogeneous trial endpoints, differing safety priorities, and distinct long-term monitoring requirements, which in turn influence trial design and evidence-generation pathways.

Therapeutic modality remains a primary determinant of development and commercialization approaches. Biologics, which encompass IL-1 inhibitors, IL-6 inhibitors, and TNF inhibitors, carry unique manufacturing and distribution demands as well as differentiated clinical profiles compared with corticosteroids and small molecule inhibitors. Biologics often warrant investment in cold-chain logistics and specialized patient support while small molecule options may offer advantages in oral administration, formulary placement, and broader prescriber uptake. Route of administration further refines these decisions: intravenous therapies often require infusion center capacity and can impose higher direct care costs, oral agents support outpatient management and ease adherence for chronic regimens, and subcutaneous formulations provide a middle ground that facilitates home administration and can improve patient convenience and retention.

Distribution channel choice directly affects patient access and the economics of care. Hospital pharmacies play a central role in administering infusion-based treatments and managing acutely ill patients, while online pharmacies and retail pharmacy networks expand reach for home-delivered biologics or oral agents and support ongoing adherence. End-user segmentation by age-adult, geriatric, and pediatric patients-introduces additional complexity because dosing strategies, safety monitoring, and formulation preferences differ across life stages. Pediatric populations, for example, require careful consideration of growth and developmental impacts and often depend on specialized centers, whereas geriatric patients bring comorbidity and polypharmacy considerations that can influence safety profiles and payer coverage decisions. Integrating these segmentation layers is essential for prioritizing development assets, optimizing route and formulation strategies, tailoring patient support, and aligning reimbursement discussions with the heterogeneous needs of clinicians and patients.

Regional imperatives and nuanced market dynamics across the Americas, Europe-Middle East-Africa, and Asia-Pacific that shape access, evidence demands, and manufacturing choices

Regional dynamics materially influence development priorities, access pathways, and commercial execution across rare autoinflammatory disease markets. In the Americas, regulatory pathways and payer systems support a strong emphasis on rapid adoption of novel biologics, robust patient advocacy networks, and advanced clinical trial infrastructure, particularly for networks that can identify and enroll patients with well-characterized genetic subtypes. Meanwhile, price sensitivity and payer scrutiny in certain markets drive manufacturers to invest in outcomes evidence and patient support services to sustain uptake. Supply-chain resilience and manufacturing proximity become key considerations where import-related costs or trade policy shifts alter total cost of therapy.

Europe, the Middle East & Africa brings a diverse spectrum of regulatory frameworks and reimbursement environments. Centralized review mechanisms in some European jurisdictions coexist with multi-country health technology assessment processes that prioritize comparative effectiveness data. This region often requires tailored health economic dossiers and real-world evidence to secure favorable access and reimbursement. Fragmentation across countries necessitates bespoke pricing and distribution strategies, and partnerships with specialty pharmacies and academic referral centers remain critical to reach rare disease patients.

In Asia-Pacific, rapid growth in clinical research capacity, increasing domestic biomanufacturing capabilities, and evolving payer systems create both opportunities and challenges. Some markets are accelerating local regulatory reforms to attract rare disease investment, while others remain constrained by limited diagnostics infrastructure and variable reimbursement policies. Strategic engagement with regional clinical networks, investment in diagnostic capacity building, and considerations around local production or licensing can be decisive in ensuring supply continuity and market entry. Across all regions, harmonizing evidence generation, aligning with local diagnostic practices, and adapting distribution strategies to the realities of each healthcare system are essential to translate scientific advances into sustainable patient access.

Strategic company behaviors including targeted biologic development, formulation innovation, diagnostic partnerships, and operational alliances that drive differentiation and access

Companies operating in this therapeutic space are adopting differentiated strategic postures to balance scientific risk, operational feasibility, and commercial potential. Leading developers prioritize pathway-specific biologics that target IL-1 or IL-6 signaling given the strong mechanistic rationale in many autoinflammatory disorders, while others pursue small molecule inhibitors or repurposed agents that may offer advantages in route of administration and cost of goods. Across the competitive landscape, organizations are investing in formulation science to enable subcutaneous or oral delivery, thereby broadening potential prescribing settings and reducing dependence on infusion centers.

Beyond product design, commercial success increasingly depends on integrated patient support ecosystems. Firms that build robust diagnostic alliances, deploy focused patient identification programs, and offer comprehensive adherence and reimbursement support gain earlier traction with prescribers and payers. Strategic partnerships-whether with contract manufacturing organizations to expand fill/finish capacity, with specialty pharmacies to enhance home-delivery models, or with diagnostic companies to co-develop companion tests-are common approaches to de-risk commercialization.

At the portfolio level, companies are hedging regulatory and pricing uncertainty through diversified pipelines and by pursuing adaptive clinical strategies that blend randomized data with real-world evidence. Mergers and alliances are being evaluated not only for pipeline synergies but also for operational capabilities in manufacturing and global distribution. Ultimately, firms that can align scientific differentiation with pragmatic access strategies will be best positioned to convert regulatory approvals into lasting patient benefit and sustainable revenue streams.

Practical strategic priorities for developers and payers to secure resilient supply chains, broaden patient access through formulation and diagnostic investments, and demonstrate sustainable value

Industry leaders should adopt a series of actionable measures to ensure resilient development pathways and durable patient access. First, invest in supply-chain diversification and contingency manufacturing to mitigate exposure to trade disruptions and to sustain cold-chain integrity for biologic therapies. Second, prioritize development of subcutaneous or oral formulations where clinically appropriate to expand treatment settings beyond infusion centers and to improve patient convenience and adherence. Third, embed health economic planning early in development to generate the comparative effectiveness and long-term outcomes evidence that payers increasingly require for high-cost therapies.

Additionally, strengthen collaborations with diagnostic providers and specialist referral networks to accelerate accurate diagnosis and streamline patient identification for trials and treatment. Invest in robust real-world evidence platforms that capture longitudinal clinical outcomes, safety signals, and health resource utilization, enabling more compelling value propositions for payers and health systems. Expand patient support services including education, adherence programs, and financial navigation to lower barriers to initiation and continuation of therapy. Embrace innovative contracting models with payers, such as outcomes-based agreements, to share risk and demonstrate value over time.

Finally, prioritize regulatory engagement across jurisdictions to align on acceptable endpoints, surrogate markers, and post-approval evidence commitments. These combined actions will enable a flexible, patient-centered commercial approach that preserves innovation incentives while addressing payer and provider concerns about affordability and long-term impact.

A methodological overview describing blended primary interviews, systematic secondary evidence synthesis, and iterative triangulation to ensure reliable, actionable insights for stakeholders

The research underpinning this analysis combined structured primary engagement with domain experts and systematic secondary evidence synthesis to ensure robust, triangulated insights. Primary inputs included in-depth interviews with clinicians specializing in autoinflammatory syndromes, supply-chain and distribution executives, regulatory affairs professionals, and patient advocacy leaders to capture operational realities and unmet needs. Secondary sources encompassed peer-reviewed clinical literature, regulatory approvals and guidance documents, published clinical trial protocols, and aggregated clinical registry reports to ground the narrative in verifiable clinical and policy developments.

Data synthesis emphasized cross-validation to reconcile differing perspectives and to identify consistent themes that persist across geographies and stakeholder groups. Methodological rigor was applied through iterative hypothesis testing, scenario analysis for trade and distribution impacts, and qualitative coding of interview transcripts to surface recurring operational barriers and opportunity areas. The research process maintained transparency about limitations inherent to rare disease work, including small patient cohorts and heterogeneity of clinical presentations, and recommendations explicitly account for these constraints by favoring adaptable and evidence-building strategies.

Ethical considerations guided engagement with clinicians and advocates, and confidentiality protections were applied where requested. The methodology prioritized practical relevance for decision-makers by focusing on actionable insight rather than speculative projections, and the full report provides appendix-level detail on interview protocols, source lists, and analytic assumptions for those seeking deeper methodological transparency.

Synthesis of scientific progress, operational imperatives, and regional trade effects defining the actionable pathway from therapeutic innovation to sustained patient access

Rare autoinflammatory diseases present a convergence of scientific opportunity and operational complexity. Advances in targeted therapies and diagnostics have created a meaningful pathway to improved outcomes, yet the realization of that potential depends on integrated strategies that address manufacturing, distribution, payer engagement, and patient identification. The interplay between therapeutic modality, route of administration, and distribution channel will determine both clinical adoption patterns and the long-term sustainability of care models across diverse patient cohorts.

Regional policy environments and trade dynamics add layers of strategic consideration, as do the distinct needs of adult, geriatric, and pediatric populations. Companies that proactively align clinical development with pragmatic access strategies-investing in formulation innovation, diagnostic partnerships, and real-world evidence-will be better positioned to navigate reimbursement scrutiny and to secure durable uptake. Decision-makers should treat supply-chain resilience, early payer engagement, and patient-centric design as core pillars of program planning rather than afterthoughts.

In conclusion, the pathway from molecular insight to patient benefit is narrowing, but success will require orchestration across scientific, operational, and commercial dimensions. Executives who integrate these elements and act with deliberate agility will convert therapeutic potential into meaningful, sustained improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rare Autoinflammatory Diseases Drug Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Il-1 Inhibitors
    • 8.1.2. Il-6 Inhibitors
    • 8.1.3. Tnf Inhibitors
  • 8.2. Corticosteroids
  • 8.3. Small Molecule Inhibitors

9. Rare Autoinflammatory Diseases Drug Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Rare Autoinflammatory Diseases Drug Market, by Indication

  • 10.1. Cryopyrin-Associated Periodic Syndromes
    • 10.1.1. Familial Cold Autoinflammatory Syndrome
    • 10.1.2. Muckle-Wells Syndrome
    • 10.1.3. Neonatal-Onset Multisystem Inflammatory Disease
  • 10.2. Familial Mediterranean Fever
  • 10.3. Hyperimmunoglobulin D Syndrome
  • 10.4. Tumor Necrosis Factor Receptor Associated Periodic Syndrome

11. Rare Autoinflammatory Diseases Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Rare Autoinflammatory Diseases Drug Market, by End User

  • 12.1. Adult Patients
  • 12.2. Geriatric Patients
  • 12.3. Pediatric Patients

13. Rare Autoinflammatory Diseases Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Rare Autoinflammatory Diseases Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Rare Autoinflammatory Diseases Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Rare Autoinflammatory Diseases Drug Market

17. China Rare Autoinflammatory Diseases Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AB2 Bio Ltd
  • 18.6. ACELYRIN, Inc.
  • 18.7. Aslan Pharmaceuticals Limited
  • 18.8. BioCryst Pharmaceuticals, Inc.
  • 18.9. CSL Behring GmbH
  • 18.10. Humanigen, Inc.
  • 18.11. Immedica Pharma AB
  • 18.12. Inmagene Biopharmaceuticals
  • 18.13. Janssen Biotech, Inc.
  • 18.14. Kiniksa Pharmaceuticals, Ltd.
  • 18.15. Mabpharm Limited
  • 18.16. Novartis AG
  • 18.17. Pharming Group N.V.
  • 18.18. Regeneron Pharmaceuticals, Inc.
  • 18.19. RPharm
  • 18.20. Swedish Orphan Biovitrum AB
  • 18.21. Takeda Pharmaceutical Company Limited
  • 18.22. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 179. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 187. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)